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Different viruses are currently being assessed for their capacity to function as anti-tumor agents, supplementing conventional cancer therapies. Here we report on the potentials of a novel oncolytic virus, the mouse hepatitis coronavirus (MHV), in destroying tumor cells *in vitro*. MHV is an enveloped positive strand RNA virus displaying strong species specificity. It has a replication cycle of only 6--9 hours, and rapidly kills murine CEACAM-expressing cells by fusion of the infected cells with their neighboring cells. To redirect MHV to human cancer cells, we produced bispecific adapter molecules binding to the virus as well as to receptors expressed on human cancer cells. The adapters were composed of the ectodomain of the CEACAM receptor coupled to single-chain antibody 425 (directed against the epidermal growth factor receptor), or to a synthetic peptide-tag (directed against an artificial His-tag receptor). Preincubation of the coronaviruses with the adapter proteins and subsequent inoculation of the infection mixes on human cancer cells resulted in receptor specific infection, and cell-cell fusion, typical for coronavirus replication. In order to produce genetically targeted oncolytic coronaviruses, we incorporated the gene encoding the peptide-tag adapter in the MHV genome in a way that during infection continuous amounts of adapter are produced, thereby enabling the progeny virus to reinfect new cells. This resulted in genetically targeted coronaviruses, which were able to specifically infect, and replicate in human cancer cells expressing the specific targeting receptor. We observed multi-round infection, cell-cell fusion, and extensive cell death. These results show that the mouse hepatitis coronavirus, normally not capable of infecting human cells, can be genetically redirected via bispecific adapters to a specific receptor expressed on human cancer cells, consequently leading to rapid cell death. This result provides interesting leads for further investigations on the use of coronaviruses as anti-tumor agents.
